|
Apr 17
|
Palatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide
|
|
Apr 14
|
Top Premarket Gainers
|
|
Apr 14
|
Palatin Appeals NYSE American Notice of Delisting
|
|
Apr 11
|
Top Midday Decliners
|
|
Mar 13
|
Here's Why Palatin Technologies (PTN) Is a Great 'Buy the Bottom' Stock Now
|
|
Feb 14
|
Q2 2025 Palatin Technologies Inc Earnings Call
|
|
Feb 14
|
Palatin Technologies Inc (PTN) Q2 2025 Earnings Call Highlights: Strategic Advances Amid ...
|
|
Feb 13
|
Palatin Reports Second Quarter Fiscal Year 2025 Financial Results and Provides Business Update
|
|
Feb 10
|
Palatin to Report Second Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on February 13, 2025
|
|
Oct 7
|
Palatin Receives Notice of Non-Compliance from NYSE American
|
|
Oct 2
|
Q4 2024 Palatin Technologies Inc Earnings Call
|
|
Oct 2
|
Palatin Technologies Inc (PTN) Q4 2024 Earnings Call Transcript Highlights: Strategic Moves and ...
|
|
Oct 1
|
Palatin Reports Fourth Quarter and Fiscal Year Ended 2024 Financial Results, Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones
|
|
Jun 21
|
Palatin Announces Exercise of Warrants for Approximately $6.1 Million Gross Proceeds
|
|
Jun 21
|
Palatin initiates Bremelanotide-PDE5i Phase II trial for ED
|
|
Jun 13
|
Palatin Technologies commences Phase II study of obesity treatment
|
|
Jun 12
|
Palatin Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of Obesity
|
|
May 16
|
Palatin Technologies Inc (PTN) (Q3 2024) Earnings Call Transcript Highlights: Navigating ...
|
|
May 16
|
Q3 2024 Palatin Technologies Inc Earnings Call
|
|
May 15
|
Palatin Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
|